-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

623.O3.6 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma Clinical Trials

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
antibodies, Biological, Adult, CRS, Leukemia, therapy sequence, Lymphoma (any), Diseases, Non-Biological, CLL, Marginal Zone Lymphoma, neurotoxicity, Therapies, Combinations, Mantle Cell Lymphoma, Adverse Events, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, enzyme inhibitors, Technology and Procedures, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant, TKI, molecular testing, NGS
Saturday, December 5, 2020: 9:30 AM-11:00 AM
Anastasios Stathis, MD, Oncology Institute of Southern Switzerland and Francisco J. Hernandez-Ilizaliturri, MD, Roswell Park Cancer Institute
No relevant conflicts of interest to declare.
9:30 AM

Michael Wang, MD1, Nirav N. Shah, MD2, Alvaro J. Alencar, MD3, James N. Gerson, MD4, Manish R. Patel, MD5, Bita Fakhri, MD, MPH6, Wojciech Jurczak, MD, PhD7, Xuan Ni Tan, MD8*, Katharine L Lewis, MBBS8, Timothy S. Fenske, MD9, Catherine C. Coombs, MD10, Ian W. Flinn, MD, PhD11, David John Lewis, MD12*, Steven Le Gouill, MD, PhD13, M. Lia Palomba, MD14, Jennifer A. Woyach, MD15, John M. Pagel, MD PhD16, Nicole Lamanna, MD17, Jonathon B. Cohen, MD, MS18, Minal Barve, MD19*, Paolo Ghia, MD, PhD20, Toby A. Eyre21*, Ming Yin22*, Binoj Nair, PhD22*, Donald Tsai, MD, PhD22, Nora C. Ku, MD22*, Anthony Mato, MD14* and Chan Yoon Cheah, MBBS8

1Department of Lymphoma and Myeloma, U.T. M.D. Anderson Cancer Center, Houston, TX
2Medical College of Wisconsin, Brookfield, WI
3Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL
4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
5Florida Cancer Specialists / Sarah Cannon Research Institute, Sarasota, FL
6Division of Hematology and Oncology, University of California, San Francisco, CA
7Department of Hematology, Maria Sklodowska-Curie National Institute of Oncology, Krakow, Poland
8Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia
9Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
10Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
11Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
12Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, United Kingdom
13Service d’hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France
14Memorial Sloan Kettering Cancer Center, New York, NY
15The Ohio State University Comprehensive Cancer Center, Columbus, OH
16Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
17Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
18Winship Cancer Institute, Emory University, Atlanta, GA
19Mary Crowley Cancer Research, Dallas, TX
20Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, MI, Italy
21Churchill Cancer Center, Oxford University Hospitals NHS Foundation Trust, Old Road, United Kingdom
22Loxo Oncology at Lilly, Stamford, CT

9:45 AM

Maria Lia Palomba, MD1, Leo I. Gordon, MD2, Tanya Siddiqi, MD3*, Jeremy S. Abramson, MD4*, Manali Kamdar, MD5*, Matthew A. Lunning, DO, FACP6, David G. Maloney, MD, PhD7, Charalambos Andreadis, MD, MSCE8*, Jon E. Arnason, MD9, Nilanjan Ghosh, MD, PhD10, Amitkumar Mehta, MD11, Scott R. Solomon, MD12, Thalia Farazi, MD, PhD13*, Jacob Garcia, MD13*, Christine Dehner, BSc13*, Ken Ogasawara, PhD, MPH14*, Jie Gao, PhD14* and Michael Wang, MD15

1Memorial Sloan Kettering Cancer Center, New York, NY
2Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
3City of Hope National Medical Center, Duarte, CA
4Massachusetts General Hospital Cancer Center, Boston, MA
5University of Colorado Cancer Center, Aurora, CO
6University of Nebraska Medical Center, Omaha, NE
7Fred Hutchinson Cancer Research Center, Seattle, WA
8Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
9Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
10Levine Cancer Institute, Atrium Health, Charlotte, NC
11University of Alabama at Birmingham, Birmingham, AL
12Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA
13Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA
14Bristol-Myers Squibb Company, Princeton, NJ
15Department of Lymphoma and Myeloma, U.T. M.D. Anderson Cancer Center, Houston, TX

10:00 AM

Zachary D. Epstein-Peterson, MD1, Connie Lee Batlevi, MD, PhD2, Philip Caron, MD, PhD1, Ahmet Dogan, MD, PhD3, Pamela Drullinsky, MD1*, John Gerecitano, MD, PhD4, Audrey Hamilton, MD1*, Paul A. Hamlin, MD1, Caleb Ho, MD3, Allison P. Jacob5*, Leana Laraque, BA2*, Matthew J Matasar, MD, MS1, Alison J. Moskowitz, MD1, Craig H. Moskowitz, MD6, Chelsea D Mullins, BS5*, Colette Owens, MD1, Gilles Salles7, Heiko Schöder, MD8*, David J. Straus, MD1, Anas Younes, MD9, Andrew D Zelenetz, MD, PhD1 and Anita Kumar, MD1

1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Memorial Sloan Kettering Cancer Center, New York, NY
3Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
4The Janssen Pharmaceutical Companies of Johnson & Johnson, West New York, NJ
5Adaptive Biotechnologies, Seattle, WA
6Department of Medicine, University of Miami Sylvester Sylvester Comprehensive Cancer Center, Miami, FL
7Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
8Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
9AstraZeneca, New York, NY

10:15 AM

Mary B. Callanan, PhD1*, Elizabeth Macintyre, PhD, MD2, Marie-Helene Delfau-Larue, MD, PhD3,4*, Catherine Thieblemont, MD, PhD5, Lucie Oberic, MD6,7*, Emmanuel Gyan, MD, PhD8, Krimo Bouabdallah, MD9*, Rémy Gressin, MD10*, Gandhi Damaj, MD, PhD11*, Olivier Casasnovas, MD12*, Vincent Ribrag, MD13, Samuel Griolet14*, Bénédicte Burlet15*, Benjamin Tournier, Ph.D16*, Sylviane Ragot, M.Sc17*, Caroline Bodet-Milin18*, Olivier Hermine19,20 and Steven Le Gouill, MD, PhD21

1University Hospital F. Mitterrand and Inserm UMR 1231, DIJON, France
2Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut national de recherche médicale (INSERM) U1151, Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, Paris, France
3INSERMU955 équipe 9, Institut Mondor de Recherche Biomédicale, Créteil, France
4Department of Immunology, Hopital Henri Mondor, Creteil, France
5Department of Hemato-Oncology, Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris, Paris, France
6Department of Hematology, Institut Universitaire Cancerologie Toulouse-Oncopole, Toulouse, France
7Department of Hematology, Purpan University Hospital, Toulouse, France
8Department of Hematology and Cellular Therapy, Tours University Hospital, UMR CNRS, François Rabelais University, Tours, France
9Department of Hematology, University Hospital of Bordeaux, Pessac, France
10Department of clinical hematology., Centre Hospitalier et Universitaire de Grenoble-Alpes, Grenoble, France
11Department of Hematology, Caen University Hospital, Caen, France
12Hematology Department, University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France
13Institut Gustave Roussy, Villejuif, France
14Centre Hospitalier Lyon Sud, Lymphoma Academic Research Organisation (LYSARC), Lyon, France
15Faculty of Medicine, University of Burgundy, INSERM 1231, Dijon University Hospital, Dijon, France
16Faculty of Medicine, University of Burgundy, INSERM1231, Dijon University Hospital, Dijon, France
17University of Burgundy, INSERM 1231, Dijon University Hospital, Dijon, France
18Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, Nantes, France
19Imagine Institute, INSERM U1163, University of Paris, Paris, France
20Clinical Hematology, Necker University Hospital, Paris, France
21Service d’hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France

10:30 AM

Michael Wang, MD1, Jacqueline C. Barrientos, MD2, Richard R. Furman, MD3, Matthew Mei, MD4, Paul M. Barr, MD5, Michael Y. Choi, MD6, Sven de Vos, MD, PhD7, Avyakta Kallam, MD8, Krish Patel, MD9, Simon Rule, MD, PhD10*, Kate Flanders, BS10*, Katti A. Jessen, PhD10, Peter C. Riebling11*, Patricia Graham, BHSA12*, Lydia King, PhD12*, Elizabeth M. Schmidt, BSN10*, Brian J. Lannutti, PhD10, David M. Johnson, BS10*, Langdon L. Miller, MD10* and Stephen E. Spurgeon, MD13

1Department of Lymphoma and Myeloma, U.T. M.D. Anderson Cancer Center, Houston, TX
2Northwell Health System, New Hyde Park, NY
3Weill Cornell Medical College, New York, NY
4City of Hope, Duarte, CA
5Wilmot Cancer Institute, Medical Director, Clinical Trial Office, Professor of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
6University of California-San Diego, San Diego, CA
7University of California-Los Angeles, Los Angeles, CA
8University of Nebraska Medical Center, Omaha, NE
9Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
10VelosBio Inc., San Diego, CA
11VelosBio Inc., Metuchen, NJ
12Ce3, Inc., Clinton, CT
13Oregon Health & Science University, Portland, OR

10:45 AM

Mats Jerkeman, MD, PhD1, Arne Kolstad, MD, PhD2*, Carsten Utoft Niemann, MD, PhD3, Kirsten Groenbaek, MD, DMSc4*, Martin Hutchings, MD, PhD5*, Annika Pasanen, MD, PhD6*, Sara Ekberg7*, Karin Fahl Wader, MD, PhD8* and Ingrid Glimelius, MD, PhD9*

1Department of Oncology, Lund University and Skane University Hospital, Lund, Sweden
2Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway
3Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen O, Denmark
4The Epi-/Genome Laboratory, Department of Hematology/Rigshospitalet, Copenhagen, DNK
5Department of Hematology; Finsen Centre, National Hospital, Copenhagen University Hospital, Copenhagen, Denmark
6Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland
7Division of Clinical Epidemiology, Dept of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
8Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
9Department of Immunology, Genetics and Pathology, Unit of Oncology, Uppsala University, Uppsala, Sweden

*signifies non-member of ASH